Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.

Cosman F, Mitlak BH, Wang Y, Pearman L, Moreira CA, Lewiecki EM, Cummings SR

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2025Cited by 4 (Europe PMC)

PMID40214193PMCIDPMC12131237DOI10.1093/jbmr/zjaf053PepBankPUB-40214193

Download PDF PubMedAsk about this study

Jump to 6 results

Summary

The goal of treatment for women at high risk of fracture who have a T-score ≤-2.5 is to mitigate fracture risk by achieving T-scores at least above -2.5. In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo. In ACTIVExtend, eligible women from the abaloparatide and placebo groups received weekly treatment with 70 mg of alendronate for 2 additional years. This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤-2.5. Logistic regression was used to predict the probability of achieving a T-score >-2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate. At baseline, 23% and 74% of women enrolled in ACTIVE had T-scores ≤-2.5 at the TH and LS, respectively. Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores >-2.5, with baseline TH T-scores as low as -2.7 for both abaloparatide and teriparatide. More than 50% of women were predicted to achieve an LS T-score >-2.5 with a baseline LS T-score as low as -3.3 for abaloparatide or -3.2 on teriparatide. Over 3.5 yr of sequential treatment with abaloparatide/alendronate, >50% of women with baseline TH T-scores ≥-2.9 and LS T-scores ≥-3.5 were predicted to achieve T-scores >-2.5, respectively. A patient's BMD at baseline and the probability of achieving target T-scores with treatment should be considered when determining that treatment should be initiated in patients at high or very high risk of fracture.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome
A model predicted >50% probability of total hip T-scores >-2.5 over 18 months with abaloparatide, for baseline scores as low as -2.7.
In plain wordsA model predicted >50% probability of total hip T-scores >-2.5 with abaloparatide over 18 months.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicablePredicted total hip T-score target
Study
n: not reported in source
Logistic regression predicting T-score target attainment from ACTIVE and ACTIVExtend data
Outcome group
Bone and joint · Musculoskeletal
Measurements
Baseline T-score for >50% predicted probability of T-score >-2.5
−2.7 T-score
abaloparatide, total hip, 18 mo
Predicted probability of reaching T-score >-2.5
> 50%
abaloparatide, total hip, 18 mo
Source sentences
Summary
Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores >-2.5, with baseline TH T-scores as low as -2.7 for both abaloparatide and teriparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo.
Summary · context
This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤-2.5. Logistic regression was used to predict the probability of achieving a T-score >-2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4021419301
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
A model predicted >50% probability of total hip T-scores >-2.5 over 18 months with teriparatide, for baseline scores as low as -2.7.
In plain wordsA model predicted >50% probability of total hip T-scores >-2.5 with teriparatide over 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePredicted total hip T-score target
Study
n: not reported in source
Logistic regression predicting T-score target attainment from ACTIVE and ACTIVExtend data
Outcome group
Bone and joint · Musculoskeletal
Measurements
Baseline T-score for >50% predicted probability of T-score >-2.5
−2.7 T-score
teriparatide, total hip, 18 mo
Predicted probability of reaching T-score >-2.5
> 50%
teriparatide, total hip, 18 mo
Source sentences
Summary
Over 18 mo of treatment, more than 50% of women were likely to achieve TH T-scores >-2.5, with baseline TH T-scores as low as -2.7 for both abaloparatide and teriparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo.
Summary · context
This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤-2.5. Logistic regression was used to predict the probability of achieving a T-score >-2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-4021419302
03HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome
A model predicted >50% probability of lumbar spine T-scores >-2.5 over 18 months with abaloparatide, for baseline scores as low as -3.3.
In plain wordsA model predicted >50% probability of lumbar spine T-scores >-2.5 with abaloparatide over 18 months.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicablePredicted lumbar spine T-score target
Study
n: not reported in source
Logistic regression predicting T-score target attainment from ACTIVE and ACTIVExtend data
Outcome group
Bone and joint · Musculoskeletal
Measurements
Baseline T-score for >50% predicted probability of T-score >-2.5
−3.3 T-score
abaloparatide, lumbar spine, 18 mo
Predicted probability of reaching T-score >-2.5
> 50%
abaloparatide, lumbar spine, 18 mo
Source sentences
Summary
More than 50% of women were predicted to achieve an LS T-score >-2.5 with a baseline LS T-score as low as -3.3 for abaloparatide or -3.2 on teriparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo.
Summary · context
This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤-2.5. Logistic regression was used to predict the probability of achieving a T-score >-2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4021419303
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
A model predicted >50% probability of lumbar spine T-scores >-2.5 over 18 months with teriparatide, for baseline scores as low as -3.2.
In plain wordsA model predicted >50% probability of lumbar spine T-scores >-2.5 with teriparatide over 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePredicted lumbar spine T-score target
Study
n: not reported in source
Logistic regression predicting T-score target attainment from ACTIVE and ACTIVExtend data
Outcome group
Bone and joint · Musculoskeletal
Measurements
Baseline T-score for >50% predicted probability of T-score >-2.5
−3.2 T-score
teriparatide, lumbar spine, 18 mo
Predicted probability of reaching T-score >-2.5
> 50%
teriparatide, lumbar spine, 18 mo
Source sentences
Summary
More than 50% of women were predicted to achieve an LS T-score >-2.5 with a baseline LS T-score as low as -3.3 for abaloparatide or -3.2 on teriparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo.
Summary · context
This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤-2.5. Logistic regression was used to predict the probability of achieving a T-score >-2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-4021419304
05HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome
A model predicted >50% probability of total hip T-scores >-2.5 over 3.5 years with sequential abaloparatide/alendronate, for baseline scores ≥-2.9.
In plain wordsA model predicted >50% probability of total hip T-scores >-2.5 with sequential abaloparatide/alendronate over 3.5 years.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicablePredicted total hip target with sequential therapy
Study
n: not reported in source
Logistic regression predicting T-score target attainment from ACTIVE and ACTIVExtend data
Outcome group
Bone and joint · Musculoskeletal
Measurements
Baseline T-score for >50% predicted probability of T-score >-2.5
≥ −2.9 T-score
abaloparatide/alendronate sequence, total hip, 3.5 yr
Predicted probability of reaching T-score >-2.5
> 50%
abaloparatide/alendronate sequence, total hip, 3.5 yr
Source sentences
Summary
Over 3.5 yr of sequential treatment with abaloparatide/alendronate, >50% of women with baseline TH T-scores ≥-2.9 and LS T-scores ≥-3.5 were predicted to achieve T-scores >-2.5, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo.
Summary · context
This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤-2.5. Logistic regression was used to predict the probability of achieving a T-score >-2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4021419305
06HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome
A model predicted >50% probability of lumbar spine T-scores >-2.5 over 3.5 years with sequential abaloparatide/alendronate, for baseline scores ≥-3.5.
In plain wordsA model predicted >50% probability of lumbar spine T-scores >-2.5 with sequential abaloparatide/alendronate over 3.5 years.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicablePredicted lumbar spine target with sequential therapy
Study
n: not reported in source
Logistic regression predicting T-score target attainment from ACTIVE and ACTIVExtend data
Outcome group
Bone and joint · Musculoskeletal
Measurements
Baseline T-score for >50% predicted probability of T-score >-2.5
≥ −3.5 T-score
abaloparatide/alendronate sequence, lumbar spine, 3.5 yr
Predicted probability of reaching T-score >-2.5
> 50%
abaloparatide/alendronate sequence, lumbar spine, 3.5 yr
Source sentences
Summary
Over 3.5 yr of sequential treatment with abaloparatide/alendronate, >50% of women with baseline TH T-scores ≥-2.9 and LS T-scores ≥-3.5 were predicted to achieve T-scores >-2.5, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In the ACTIVE trial, 2463 women with osteoporosis aged 49-86 yr were treated for 18 mo with abaloparatide (80 μg), teriparatide (20 μg), or placebo.
Summary · context
This post hoc analysis of ACTIVE and ACTIVExtend included women with baseline TH or LS T-scores ≤-2.5. Logistic regression was used to predict the probability of achieving a T-score >-2.5 at the TH or LS during 18 mo of treatment with abaloparatide or teriparatide and during 3.5 yr with the sequence of abaloparatide/alendronate compared to placebo/alendronate.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4021419306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.

Summary

Results from this study6

Studies that did not test the peptide alone6

Version history

Subjects

Publication types

MeSH terms

Keywords